拉尼菲布拉诺降低了炎症,并改善了 Lysosomal 酸脂酶缺乏的小鼠中的失脂症
Ivan Bradić1,2, Nemanja Vujić1, Katharina B Kuentzel1
1Division of Molecular Biology and Biochemistry, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria.
Gastro hep advances
|September 16, 2024
概括
在溶酶酸脂酶缺乏症 (LAL-D) 的小鼠模型中,Lanifibranor治疗减少了炎症并改善了脂质配置. 需要进一步的研究来探索其作为人类LAL-D疗法的潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- lysosomal酸脂酶缺乏症 (LAL-D) 是一种导致严重肝损伤的遗传疾病.
- 酶替代疗法 (ERT) 在改善肝脏组织病理方面显示出可变的疗效.
- 作为PPAR激动剂的拉尼非布拉诺已经在治疗与代谢功能障碍相关的脂肪肝炎方面展现出有前途的表现.
研究的目的:
- 在LAL-D小鼠模型中研究 lanifibranor 对肝炎和脂质失调的潜在治疗作用.
- 评估 lanifibranor 对肝脏蛋白质和新陈代谢特征的影响.
主要方法:
- 雌性LAL-缺乏 (Lal-/-) 的小鼠每天被用lanifibranor或载体治疗21天.
- 评估了身体和器官的体重,血脂质,脂蛋白和血液学参数.
- 进行肝脏蛋白质学和代谢学,以分析分子变化.
主要成果:
- 拉尼菲布拉诺治疗没有改变总体体重,但稍微影响了器官重量.
- 观察到显著的蛋白质变化,包括脂质代谢和过氧体/线粒体蛋白的上调,以及炎症标志物的下调.
- 肝脂水平和组织学保持不变,而血三糖醇和胆固醇下降,脂蛋白概况得到改善.
结论:
- 在LAL-D小鼠中,Lanifibranor对肝炎和脂质失调有积极的影响.
- 与ERT联合治疗可能会增强LAL-D表型的改善.
- 临床试验是合理的,以评估lanifibranor在人类LAL-D治疗中的有效性.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747